comparemela.com

Latest Breaking News On - Charles wykoff - Page 1 : comparemela.com

Keeping A Watchful Eye: Safety Reports in Geographic Atrophy Landscape

A headline year for retina disease drug development concurrently brought about research and discussion into the safety outcomes of these new agents.

United statesSan franciscoIapocec apellisDavid lallyKunzmannk apellisDilsher dhootVeeral shethIapocec charles wykoffCharles wykoffNathan steinleAvacincaptad pegolIapocec pegcetacoplanIapocec nathan steinleUniversity retinaApellis pharmaceuticalsMacula associates

Study Shows Tarcocimab May Improve Diabetic Retinopathy

A phase 3 trial showed that tarcocimab, a biopolymer with a vascular growth factor antibody, improved vision and anatomical markers in patients with early stage diabetic retinopathy.

Friuli venezia giuliaUnited statesPaolo lanzettaCharles wykoffKodiak sciencesUniversity of udineAmerican academy of ophthalmologyBlanton eye institute of houston methodist hospitalRetina consultantsBlanton eye instituteHouston methodistAmerican academyDiabetic retinopathy severity scaleRetinal diseaseDiabetes mellitus type 2Iabetes mellitus type ii

Ocugen, Inc Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease

MALVERN, Pa., Nov. 10, 2023 Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today.

United statesCharles wykoffShankar musunuriOcugen incHead of communicationsExchange commissionNuclear hormone receptorStargardt diseaseOrphan receptorRetina consultantsPrivate securities litigation reform act

VEGF-Targeted Antibody Conjugate Gets a Win in Nonproliferative Diabetic Retinopathy

Some degree of improvement in disease status in 70% of patients treated with tarcocimab

United statesVictor perlrothCharles bankheadCharles wykoffUniversity of iowaKodiak sciencesAmerican society of retina specialistsBlanton eye instituteAmerican academy of ophthalmologyDiabetic retinopathy severity scaleHouston methodist hospitalAmerican academyAmerican societyRetina specialistsJames folkMedpage today

The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)

SYFOVRE demonstrated clinically meaningful reductions in GA lesion growth in as few as six doses per yearOnly treatment approved for use beyond 12.

United kingdomUnited statesJeffrey heierCharles wykoffLissa pavlukCaroline baumalMeredith kayaResearch groupExchange commission onApellis pharmaceuticals incExchange commissionLancet glob healthRetina consultantsEleonora ladGeographic atrophySafety information

vimarsana © 2020. All Rights Reserved.